Speed Beats Size: Why Ortho Startups Must Set Time Goals, Not Milestone Goals
In orthopedics, we have been conditioned to worship the milestone. We build Gantt charts around design freezes, cadaver labs, 510(k)
In orthopedics, we have been conditioned to worship the milestone. We build Gantt charts around design freezes, cadaver labs, 510(k)
Every Monday I share a startup that I really like. I call it the Red-Hot Innovator of the Week. If
This week, surgical robotics shifted from hardware to software as Zimmer Biomet, DePuy Synthes, and THINK Surgical proved the surgical
“Joint replacement is one of the most successful procedures in modern medicine… until the patient walks out of the OR.“
Most orthopedic startups die in the same valley of death: massive inventory burn, bloated overhead, and getting squeezed to death
“It is a lot better to walk alone than with a crowd going in the wrong direction.” — Richard Feynman
I have seen super-smart MBA types try to run startups. It rarely works. The idea of MBAs never belonged in
Every Monday I share a startup that I really like.I call it the Red-Hot Innovator of the Week. If you
This week let’s look at the macro financials and trends (as most public orthos have posted Q3 earnings) and some
Let’s have some real talk about total joint procedure volumes in the US. The rise of GLP-1 receptor agonists like
Tiger’s Take: S+N Joins the “GLP-1 Denial” narrative. Their Q3 guidance cut and failed DePuy Synthes merger talks mask a
Have you noticed this in our industry ? Every phone call. Every email. Every LinkedIn message. Every text. Somebody is
The surgeons still want to operate. The patients still need new hips and knees. The insurers are saying no. That’s
Every Monday I share a startup that I really like.I call it the Red-Hot Innovator of the Week. If you
Great innovation ecosystems in orthopedics are rarely born from academic theories or top-down economic planning; they are seeded by dynamic,
EBITDA can look fantastic while an orthopedic company is quietly bleeding cash. I’ve watched it happen more than once. You
Most companies talk about innovation.Very few can actually digest it. Metabolism is the speed and efficiency with which a company
We all heard about the DePuy + S&N merger talks fell through last week. The media framed the late collapse
Every Monday I share a startup that I really like.I call it the Red-Hot Innovator of the Week. If you
The theme of last week was strategic consolidation, the hard truth about corporate governance, and the relentless flow of private
I used to think contingency recruiting was the best—and only—way to find talent for an orthopedic company. But the experience
In order to predict the future game-changers in orthopedics, it can be helpful to look back at history. Let’s go
NASS just packed up in San Antonio, and the press releases are still landing. Most of it is noise. But
The low-hanging fruit of AI in orthopedics is not a robot. If the metric does not move, stop. Orthopedics does
Every Monday I share a startup that I really like. I call it the Red-Hot Innovator of the Week. This
The theme of last week was big strategic repositioning and direct category combat. J&J reported Q3 ortho growth of 3.4%
Most orthopedic startups die the same way. They spend years, and a lot of other people’s money, designing and manufacturing
Sometimes my readers write great content, such as this substack article. Asher has did this. By cutting through standard industry
Selling Joints Under the New CMS Rules Medicare joint replacement is officially a permanent bundled-care market—not a pilot, not a
High-Level Strategy Stryker isn’t taking a standard gamble on soft-tissue robotics—it’s executing a calculated, low-risk breach into one of MedTech’s
Every Monday I share a startup that I really like. I call it the Red-Hot Innovator of the Week. This
Summary This was a payment week dressed up as a leadership week. CMS announced CJR-X, a nationwide mandatory joint replacement
Stryker has had only three CEOs since 1977, and each one roughly doubled or tripled the company. John Brown built
This is a big one for our industry. Centinel Spine will be testing the public markets soon. Below I will
Here we go again. Robots still don’t beat a good manual joint replacement. The UK just put a number on
Measuring the right metrics will help your company be successful. Surgeons will tell you they love the implant. Reps will
Every Monday I share a startup that I really like. I call it the Red-Hot Innovator of the Week. As
Quick Summary before the Deep Dive and Tiger’s Takes. Sector Notable Move Key Strategic Implication SI / Compromised Bone SI-BONE
Every week I talk with orthopedic founders who are raising money to fight the same three wars at once: They
Imagine if someone had visibility into all early orthopedic innovation. Even more specifically, if someone had early discussions with startups
ORTHOWORLD correctly estimated the worldwide spine market at $11.1 billion in 2025, up 3.3% from $10.8 billion the year before.
Every week I talk with orthopedic founders who are asking the wrong question: How do we get big enough? That
Every Monday I share a startup that I really like. I call it the Red-Hot Innovator of the Week. As
Ortho Conferences are still important, not for sales leads, but they tell us who launches. OTA in Nashville put pelvic
Let me throw out a theory. Orthopedics is getting harder and harder for the small ortho company to gain market
Swiss extremity and CMF specialist Medartis Holding AG bought the M.A.R.C. Institute (Miami Anatomical Research Center) in Doral, Florida. The
I hear this request all the time. Ortho executives call and say, “I need an Engineer.” That’s the wrong request.
I wrote this article to better understand how our orthopedic Orphans ended up in such a no-man’s-land, why they cannot
Every Monday I share a startup that I really like. I call it the Red-Hot Innovator of the Week. There
Conference weeks are about what you can put in a tray, not what you can put on a slide. AOFAS